LUNAPHORE-TECHNOLOGIES
14.1.2021 14:02:40 CET | Business Wire | Press release
Lunaphore Technologies SA, a Swiss life-sciences company developing innovative next-generation equipment for cancer research, announces the formation of its Scientific Advisory Board (SAB) with the appointment of two experts in the immuno-oncology (I-O) field to provide strategic advisory support to the company’s R&D activities and product portfolio development.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210114005435/en/
The role of the SAB will be to bring strategic insights that will enable Lunaphore to become leaders in the field of high-dimensional analysis of tissue samples. The SAB will support as well in the establishment of scientific partnerships with key stakeholders for the coming years.
The new Lunaphore SAB will be comprised of the following members:
- Prof. Paolo A. Ascierto, MD
Dr. Paolo A. Ascierto is the Director of the Department of Melanoma, Cancer Immunotherapy and Development Therapeutics at the National Tumor Institute in Naples, Italy. Professor Ascierto’s research interests include the genetics and proteomics of melanoma, assessment of new molecular markers for tumor progression, biochemical and immunological monitoring, immunotherapy and vaccination treatments in solid tumors, and combination strategies with I-O. He is a member of the Steering Committee of Society of Melanoma Research (SMR) and the Board of Directors of Society of ImmunoTherapy of Cancer (SITC), President of the Fondazione Melanoma Onlus, and of Campania Society of ImmunoTherapy of Cancer (SCITO). He is an Associate Editor for Onco-Immunology of Annals of Oncology, Chief Section Editor for Combination Strategies section of Journal of Translational Medicine, and Associate Editor of Journal of ImmunoTherapy of Cancer. He has been the Principal Investigator in over 100 clinical trials and is the author of more than 450 publications in peer-reviewed journals.
- Dr. Jérôme Galon
Dr. Jérôme Galon is the Director of Research at INSERM (French National Institute of Health and Medical Research), and Head of the Laboratory of Integrative Cancer Immunology at the Cordeliers Research Center in Paris, France. Dr. Galon defined the concept of cancer immune-contexture, pioneered the Immunoscore and is PI of the Immunoscore worldwide consortium. This scientific contribution was acknowledged by many awards such as the William B. Coley Award, the Award from the National Academy of Science, from the National Academy of Medicine, and European Inventor Award 2019. He is the co-founder of HalioDx and the Chairman of its Scientific Council.
“I am excited to have such great experts in I-O join our SAB,” said Dr. Dupouy, CTO at Lunaphore. “Their expertise in the field will be key to focus our research efforts on the most promising I-O applications, as well as to expand our scientific collaborations worldwide.”
"The key for the immune responsiveness is in the tumor microenvironment,” noted Dr. Ascierto. “Lunaphore has a technology which can potentially make such evaluation easier and greatly contribute to the research field of immunotherapy."
“Lunaphore is developing rapid automated staining instruments based on an innovative microfluidic technology with great potential for multiple research applications,” Dr. Galon said. “I look forward to the next generation hyper-plex immunofluorescence instruments.”
About Lunaphore
Lunaphore Technologies S.A. is a Swiss company transforming the field of tissue analytics in cancer research through the development of innovative staining and imaging technology platforms. The award-winning technology at its core is called FFeX (Fast Fluidic Exchange). Using high-precision microfluidics, complex assays can be automated, extracting comprehensive data much faster than current techniques. Lunaphore was founded in 2014 with the vision of bringing –omics like approaches to tissue analytics and has been recognized as one of the most innovative companies internationally. For further information on Lunaphore and its products, please visit www.lunaphore.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210114005435/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Unlocking Digital Gold’s US$700bn Opportunity19.10.2026 18:00:00 CEST | Press release
The digital gold market, worth US$45–55bn today, could unlock up to US$700bn in latent demand, according to new research from World Gold Council and Boston Consulting Group. The report points to substantial untapped appetite among retail investors, with nearly nine in ten surveyed saying they would consider digital gold under the right conditions. The US$700bn opportunity represents the report’s estimate of total latent demand that could be released if today’s barriers to adoption were removed, rather than a near-term forecast. The report’s five-year base case sees digital gold growing by around 27% a year to US$160–170bn by 2031. That could rise to US$270–280bn over the same time if more barriers fall faster. Momentum is already building as financial markets undergo a broader digital transformation, bringing tokenised investment products increasingly into the mainstream. Tokenised gold, one segment of the digital gold market alongside vaulted digital gold, has grown fivefold in value
Roquette Brings Broad Portfolio of Excipient Solutions and Technical Expertise to AAPS PharmSci 360 202619.10.2026 16:00:00 CEST | Press release
Roquette, a global leader in plant-based ingredients, excipients and pharmaceutical solutions, will showcase its expansive portfolio of excipients, capsules, coatings, and biopharma solutions at AAPS PharmSci 360 2026. The conference and trade show will take place October 26-28 in New Orleans, Louisiana, USA. At Booth 1100 in the exhibit hall, Roquette’s Health & Pharma Solutions team will share their expertise across controlled-release technologies, hydroxypropyl beta-cyclodextrins, and sustainable formulation approaches, alongside a comprehensive portfolio of innovative solutions designed to address the evolving needs of pharmaceutical developers. “AAPS PharmSci 360 is a key opportunity to share our latest innovations, as well as highlight the breadth and depth of our scientific know-how that helps our customers solve complex formulation challenges,” said Peter Freed, Head of Technical Service & Development North America for Roquette’s Health & Pharma Solutions Business Unit. “From a
TestGorilla Survey: Recruiters are Faster with AI, but Not More Confident They’re Finding the Right Candidates19.10.2026 15:00:00 CEST | Press release
TestGorilla survey of 1,428 US talent professionalsshows nearly two in three now spend an hour or more manually checking candidates identified by AI AI made finding candidates faster for 72% of US recruiters over the last 12 months, according to TestGorilla's Recruiting in 2026 report, a survey of 1,428 US talent professionals. That speed, however, did not make them any more confident they had found the right person. In fact, of the recruiters that claim AI has made them faster, a third reported no gain in confidence at all, and 18% say their confidence in the match actually fell. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019723138/en/ Recruiters report gains in speed from AI but not in certainty - TestGorilla’s Recruiting in the AI era 2026 report Recruiters are making up the difference themselves, by hand. Of those recruiters, 67% now spend an hour or more manually checking a single candidate before they trust that
Fortanix Announces Confidential AI for Enterprise Grade Kubernetes Workloads on CNCF® Confidential Containers (CoCo)19.10.2026 15:00:00 CEST | Press release
Industry leaders including NVIDIA, Alpha Compute, AMD, Cisco, CrowdStrike, Deepgram, Dell Technologies, Eleven Labs, Fujitsu, Gnani, H2O.ai, HPE, Intel, Klique, Personal AI, Rafay, Red Hat, Resemble AI, Spectro Cloud, Supermicro, Technology Innovation Institute (TII), TELUS and VAST Data support the advancement of secure enterprise AI adoption, enabling enterprises to run frontier AI models, AI agents and AI applications on Kubernetes Fortanix® Inc., a global leader in data and AI security and pioneer of Confidential Computing, today announced support for CNCF Confidential Containers (CoCo) in Fortanix Confidential AI, enabling organizations to run AI workloads on Kubernetes inside hardware-based Trusted Execution Environments (TEEs), on confidential CPUs and GPUs. Enterprises keep the speed and agility of containers while protecting sensitive data, AI models, agents, and applications in use, so they can support their regulatory compliance efforts, scale AI across the business, and ado
Rimini Street to Report Third Quarter 2026 Financial Results on October 29, 202619.10.2026 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on October 29, 2026. The company will host a conference call and webcast on that date to discuss the third quarter 2026 results and the fourth quarter 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019039553/en/ Rimini Street to Report Third Quarter 2026 Financial Results on October 29, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom